Mavyret and Imbruvica are growing fast, but AbbVie still depends on it's flagship rheumatoid arthritis therapy, Humira, for the lion's share of its growth, and 59% of its total revenue. Unfortunately, its main patent in the U.S. has already expired, and it looks like it will begin facing competition from less expensive biosimilars in 2023.